Welcome to the spotlight on drug target validation
Have a look at our spotlight, including access to editorials, peer-reviewed journal content from our partner journals and more exclusive content.
Translating a potential new therapeutic from the research laboratory to pre-clinical and clinical trials is a costly and time consuming endeavor, taking around 12 years and costing close to US$1 billion on average. The majority of drugs that fail to complete the development process do so due to efficacy; indicating that the wrong target was pursued. Developing a drug for a novel target that hasn’t been effectively validated is therefore a waste of time and money.
The mechanism of action of potential lead therapeutics and their particular targets can be complex, making understanding and validating the drug target challenging. With a wide range of techniques available, it can also be difficult to identify the most appropriate method for your lead therapy and target.
This spotlight will aim to review the challenges in accurate and efficient drug target validation. We will also cover recent developments in methods and techniques as well as commenting on notable new therapeutic targets identified in recent years.
- Have your say! The spotlight survey is here
- Conference: MCN at the Charles River Translational Target Validation Symposium
- Poster: target discovery and validation in systemic sclerosis
- Product profile: capture compound mass spectrometry
- Slides: genome-wide association to the clinic
- Expert interview with Ian Waddell (Charles River Laboratories)
- Interview with Professor Ian Glibert
- ‘The ultimate validation of a target is a successful clinical trial’: an interview with Maya Ghoussaini
- Biologics for evaluating drug targets: an interview with Michael Schwenkert
- Effective validation of drug targets: an interview with Lyn Jones
- DXS as a target for structure-based drug design
- Drugging the undruggable: targeting challenging E3 ligases for personalized medicinal
- Review examines advances in kinase enzymes and inhibitors for cardiovascular disease treatment
- PI3K/Akt/mTOR pathway: a potential target in rheumatoid arthritis?
- Neurodegenerative drug discovery: building on the past, looking to the future
- Strategies in the discovery of novel antifungal scaffolds
- High-throughput patch clamp screening in human α6-containing nicotinic acetylcholine receptors
- Challenges in the design of reliable immuno-oncology mouse models to inform drug development
- Pseudokinases: update on their functions and evaluation as new drug targets
- Potential new target for Alzheimer’s treatment
- Potential new transcription factor target for malaria identified
- CRISPR-Cas9 approach identifies new drug targets to aid cancer immunotherapy
- New drug target identified for glioblastoma treatment
- New potential target for preventing and treating colon cancer
- Novel data network for Huntington’s disease could identify drug targets
- Gene mutation may provide novel drug targets for rare kidney and liver disease
- Novel screening method could identify new targets in glioblastoma
- Drug discovery in the era of big data
- New collaboration for target discovery
- Novel drug target brings hope to field of pediatric oncology
NOW LIVE: visit our spotlight for the latest news and research in drug target validation >> https://t.co/1waPIPBnMc @CRiverLabs #MCNdrugtargets #drugtargetvalidation pic.twitter.com/Vxnuq7wOuN
— MedChemNet (@MedChemNet) 17 January 2018